The latest collection price of the heavy anticancer star drug Regofibril has dropped to a minimum of more than 4 yuan per tablet. The reporter learned at the scene of the tenth batch of drug collection that the anti-tumor drug Regofibril tablets with annual sales of more than 1 billion yuan have been auctioned by this collection, and the price has almost dropped to between 4 yuan and 6 yuan, which is 90% lower than the price limit. Nanjing Zhengda Tianqing is expected to win the bid in the first round of quotation. Regofibril can treat colorectal cancer, liver cancer and other cancers. Its original research manufacturer is Bayer, which occupies almost all the market share in China. The price of this collection is about 172 yuan per tablet. (science and technology innovation board Daily)German two-year bonds recovered their decline and the yield was flat at 1.95%.Huachuang Securities: It was first rated as "recommended" by Zangge Mining, with a target price of 33.3 yuan. Huachuang Securities Research Report pointed out that Zangge Mining (000408.SZ) is an important producer of potassium lithium salt and copper in China, with a high dividend return to shareholders. The company actively arranges high-quality potash resources at home and abroad: three major projects, namely, Heibei potash mine in Dalangtan, Alkali-Shishan potash mine and the eastern part of deep brine potash mine in Xiaoliangshan-Dafengshan area, are steadily promoted in China, with a total exploration right of 1,400 square kilometers; Overseas has signed a potash exploration agreement with Laos. At present, the exploration report and potash mine reserve certificate have been obtained. It is estimated that the total amount of potassium chloride resources in Setani County and Ba 'e County is 984 million tons. It is estimated that the output of the first phase of potassium chloride project will be 1 million tons/year, and the scale of potassium chloride production is expected to double in the future. The company is an important manufacturer of potassium and lithium in China, and Julong Copper is expected to inject strong kinetic energy into the company's growth. Considering that Mamicho Mining has not been consolidated at present, it is estimated that the company will realize a net profit of 25.0/27.7/4.29 billion yuan in 24-26 years, which is -27%, +11% and +54.9% respectively. In 2025, it can be compared with the company's average valuation of 19 times, giving the company a valuation of 19 times in 2025, corresponding to the target price of 33.3 yuan, covering for the first time and giving a "recommended" rating.
Volkswagen's board of directors tends not to close large German factories, and Volkswagen's board of supervisors tends not to close large German factories to cope with the cost crisis of the automaker, but no final agreement has been reached. It is reported that members of the board of directors discussed stopping the production of the Dresden factory and selling the Osnabrü ck factory.ECB: Most indicators show that the inflation rate will stabilize at 2%.Market news: Brazilian President Lula should be able to leave the hospital early next week.
Dongyang Guangyao submitted a prospectus to be listed in Hong Kong by way of introduction. On December 11th, Dongyangguang Pharmaceutical, the controlling shareholder of Dongyangguang Changjiang Pharmaceutical, submitted a prospectus to the Hong Kong Stock Exchange to be listed in Hong Kong by way of introduction, and the exclusive sponsor was CICC.According to a poll released by The Israel Times recently, 66% of the Israeli respondents believe that Netanyahu should leave politics, and only 27% of the people support him.The average annual salary of doctors is 690,000, and the fixed income accounts for 70%. On the afternoon of December 10th, National Health Commission held a press conference in Shenzhen around the promotion of Sanming's medical reform experience. Relevant officials in Guangdong, Guangzhou and Shenzhen introduced the local medical reform including centralized procurement, price adjustment and salary reform. In 2012, the Shenzhen Municipal People's Government fully invested in introducing the modern management mode of the University of Hong Kong and established the Shenzhen Hospital of the University of Hong Kong. From the details of space design and department name, we can feel that this hospital is different from ordinary mainland hospitals, and the difference in internal system may be even greater-the average annual salary of doctors in this hospital is 690,000 yuan, which is 4.8 times that of the local social wage, of which the fixed salary accounts for 70% and the performance appraisal is 30%. Generally speaking, performance income accounts for a large part of doctors' income. The reporter interviewed two doctors in tertiary hospitals in Beijing, and their performance pay accounted for about 60-70%, which was significantly higher than the fixed salary. In a set of internal data presented by Xu Xiaoping, secretary of the Party Committee of Shenzhen Hospital of the University of Hong Kong, the salary structure of three well-known 3A hospitals in Beijing, Sichuan and Zhejiang is listed, showing that the proportion of fixed income ranges from 20% to 47%. (Beijing News)
Strategy guide
12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
12-14